Inovio Pharmaceuticals Inc
F:GBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inovio Pharmaceuticals Inc
F:GBM
|
US |
|
Centuria Capital Group
ASX:CNI
|
AU |
|
MPC Energy Solutions NV
F:5IX
|
NL |
|
A
|
Actic Group AB
STO:ATIC
|
SE |
|
D
|
Dynasty Ceramic PCL
SET:DCC
|
TH |
|
SIIX Corp
TSE:7613
|
JP |
|
C
|
Consti Oyj
OMXH:CONSTI
|
FI |
|
Cadre Holdings Inc
NYSE:CDRE
|
US |
|
Shanghai Electric Group Co Ltd
OTC:SIELF
|
CN |
|
X
|
Xiamen International Port Co Ltd
F:XRG
|
CN |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
US |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
US |
|
Abb Ltd
F:ABJA
|
CH |
|
A
|
Alphabet Inc
F:ABEC
|
US |
Wall St Price Targets
GBM Price Targets Summary
Inovio Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
GBM is 5.972 EUR with a low forecast of 3.1 EUR and a high forecast of 10.744 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GBM's stock price target?
Price Target
5.972
EUR
According to Wall Street analysts, the average 1-year price target for
GBM is 5.972 EUR with a low forecast of 3.1 EUR and a high forecast of 10.744 EUR.
What is the Revenue forecast for Inovio Pharmaceuticals Inc?
Projected CAGR
163%
Over the last 13 years, the compound annual growth rate for Revenue has been -27%. The projected CAGR for the next 8 years is 163%.